Stock Analysis·← Pickers

PEPG

PepGen Inc.

PepGen Inc. (PEPG) is currently in a range/mixed trend, above the 50-day MA but below the 200-day MA. RSI is at 74.4 (overbought), with 1/3 trend checks passing.

Price
$2.40
2026-07-16
Trend score
1/3
Range / Mixed
RSI (14)
74.4
Overbought
Price above MA50Price above MA200MA50 above MA200
Change stock
Search another ticker to view its stock analysis page.
Chart View

PEPG with MA50 and MA200

7.175.634.092.551.0107/3110/2401/2204/1707/15
PEPG2025-07-312026-07-15
PriceMA50MA200
Technical Indicators

Key levels & signals

MA50
$1.71+40.12% vs price
MA200
$4.06-40.85% vs price
RSI (14)
74.4Overbought zone
MACD Signal
BullishMomentum above signal
Macro Support
Not identifiedNo repeated weekly support zone found
Support Quality
Volume data unavailable
Chart Summary
Trend summary for PEPG

PepGen Inc. (PEPG) currently looks more uncertain than directional, with a fairly mixed technical picture. The latest available price is $2.40, and 1 of 3 core trend checks are currently passing. Price is trading above the 50-day moving average by 40.1% and below the 200-day moving average by 40.9%.

Momentum and stretch context

PEPG currently has an RSI reading of 74.4, which suggests stronger momentum and a more stretched short-term backdrop. Trend traders may still find that attractive, while more patient traders may prefer to wait and see whether the stock cools off first.

What traders may watch next

Because PEPG is showing stronger momentum inside a more extended backdrop, the next step is often about timing rather than direction. A stock can keep pushing higher, but many traders will still watch for whether the move stays orderly or starts to look too stretched to offer a comfortable entry.

Company profile

About PepGen Inc.

PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
CEO
James McArthur
Employees
56
Market cap
$166.0M
Beta
1.88
52-week range
$1.01 – $7.80
Dividend
No
Exchange
NASDAQ
Country
US
IPO date
6 May 2022
ISIN
US7133171055
CUSIP
713317105
Website
pepgen.com
Company profile data from Financial Modeling Prep. PEPG listed on NASDAQ.
Learn More

Learn the indicators behind this page

Explore More

More stock opportunities

FAQ

Common questions about PEPG

Is this page a buy or sell recommendation?

No. This page is designed to help you review chart structure, momentum and technical context more quickly, but it is not personal financial advice.

Why can a stock look bullish and overbought at the same time?

Strong trending stocks can still become stretched in the short term. That is why trend traders and dip buyers can read the same chart differently.

What should I do next after reading this page?

Open the full dashboard, review the chart in more detail, compare indicators, and decide whether the setup still makes sense within your own process.